Instil Bio Q4 2022 Earnings Report $20.97 -0.45 (-2.10%) As of 01/17/2025 04:00 PM Eastern Earnings HistoryForecast Instil Bio EPS ResultsActual EPS-$8.20Consensus EPS -$9.00Beat/MissBeat by +$0.80One Year Ago EPSN/AInstil Bio Revenue ResultsActual RevenueN/AExpected Revenue$1.00 millionBeat/MissN/AYoY Revenue GrowthN/AInstil Bio Announcement DetailsQuarterQ4 2022Date3/31/2023TimeQ4 2022 Earnings ReleaseConference Call ResourcesTIL Earnings History Instil Bio Earnings HeadlinesInstil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific AntibodyJanuary 14, 2025 | globenewswire.comInstil Bio upgraded to Buy from Hold at JefferiesJanuary 7, 2025 | markets.businessinsider.comThis red-hot crypto opportunity could slam shut soonThe situation is clear: Crypto is a HUGE hit with investors. Bitcoin became so outrageously popular that early adopters had a shot at absolutely outrageous 14,510% gains or more over the last decade. And it’s far from the only time traders had a shot at obscene gains on crypto. With Ethereum, lucky traders who put $1,000 in 5 years ago and held through the ups and downs would have seen it turn into a staggering $709,740. And now there is a NEW blockchain seeing rapid adoption…January 21, 2025 | Wealthpin Pro (Ad)Jefferies Upgrades Instil Bio (TIL)January 7, 2025 | msn.comInstil Bio Stock Soars After Jefferies Upgrade On 'Early Mover' Cancer Drug Candidate: Retail JubilantJanuary 7, 2025 | msn.comInstil Bio Secures Loan to Refinance FacilityDecember 23, 2024 | tipranks.comSee More Instil Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Instil Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Instil Bio and other key companies, straight to your email. Email Address About Instil BioInstil Bio (NASDAQ:TIL), a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.View Instil Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings ICICI Bank (1/22/2025)Kinder Morgan (1/22/2025)Amphenol (1/22/2025)Abbott Laboratories (1/22/2025)Johnson & Johnson (1/22/2025)Procter & Gamble (1/22/2025)Travelers Companies (1/22/2025)Progressive (1/22/2025)GE Vernova (1/22/2025)CSX (1/23/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
